RhumbLine Advisers
FULC icon

RhumbLine Advisers’s Fulcrum Therapeutics FULC Stock Holding History

RhumbLine Advisers’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Buy
73,443
+7,268
+11% +$44.2K ﹤0.01% 3137
2026
Q1 		$508K Buy
66,175
+10,462
+19% +$97K ﹤0.01% 2601
2025
Q4 		$630K Sell
55,713
-13,659
-20% -$139K ﹤0.01% 2528
2025
Q3 		$638K Sell
69,372
-13,878
-17% -$100K ﹤0.01% 2531
2025
Q2 		$573K Sell
83,250
-5,743
-6% -$30.7K ﹤0.01% 2599
2025
Q1 		$256K Buy
88,993
+386
+0.4% +$1.42K ﹤0.01% 2980
2024
Q4 		$416K Buy
88,607
+1,399
+2% +$5.16K ﹤0.01% 2782
2024
Q3 		$311K Sell
87,208
-4,224
-5% -$31.3K ﹤0.01% 3002
2024
Q2 		$567K Buy
91,432
+89,775
+5,418% +$680K ﹤0.01% 2582
2024
Q1 		$15.6K Hold
1,657
– – ﹤0.01% 3799
2023
Q4 		$11.2K Hold
1,657
– – ﹤0.01% 3849
2023
Q3 		$7.36K Sell
1,657
-3,134
-65% -$13.7K ﹤0.01% 3922
2023
Q2 		$15.8K Sell
4,791
-70,716
-94% -$208K ﹤0.01% 3853
2023
Q1 		$215K Buy
75,507
+15,777
+26% +$141K ﹤0.01% 2722
2022
Q4 		$435K Buy
59,730
+9,003
+18% +$58.7K ﹤0.01% 2532
2022
Q3 		$410K Buy
50,727
+3,200
+7% +$22.9K ﹤0.01% 2588
2022
Q2 		$233K Buy
47,527
+13,412
+39% +$131K ﹤0.01% 2872
2022
Q1 		$807K Buy
34,115
+2,408
+8% +$34.1K ﹤0.01% 2220
2021
Q4 		$561K Buy
31,707
+1,508
+5% +$29.9K ﹤0.01% 2463
2021
Q3 		$852K Buy
30,199
+7,724
+34% +$146K ﹤0.01% 2298
2021
Q2 		$236K Buy
22,475
+10,120
+82% +$102K ﹤0.01% 2876
2021
Q1 		$146K Buy
12,355
+490
+4% +$6.06K ﹤0.01% 2890
2020
Q4 		$139K Buy
11,865
+1,250
+12% +$14.1K ﹤0.01% 2915
2020
Q3 		$84K Sell
10,615
-2,110
-17% -$25.4K ﹤0.01% 2895
2020
Q2 		$233K Buy
+12,725
New +$200K ﹤0.01% 2697

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RhumbLine Advisers's FULC Position: Q2 2026 in Review

RhumbLine Advisers increased its Fulcrum Therapeutics (FULC) stake by 11% in Q2 2026, buying an estimated $44.2K and bringing the position to 73,443 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

RhumbLine Advisers first reported a position in FULC in Q2 2020 and has held it in 25 quarters since. The position peaked at $852K in Q3 2021. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • RhumbLine Advisers held 73,443 shares of Fulcrum Therapeutics worth $269K as of Q2 2026.
  • RhumbLine Advisers bought 7,268 Fulcrum Therapeutics shares in Q2 2026, an estimated $44.2K.
  • Fulcrum Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3137 holding.
  • RhumbLine Advisers first reported a position in Fulcrum Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • RhumbLine Advisers's Fulcrum Therapeutics position peaked at $852K in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.